Murdych T, Weisdorf D J
Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Bone Marrow Transplant. 2001 Aug;28(3):283-7. doi: 10.1038/sj.bmt.1703133.
Cardiac complications may result from high-dose chemotherapy or irradiation administered during the conditioning phase of bone marrow and blood stem cell transplantation (BMT). To assess the frequency of clinically serious cardiac toxicity related to the acute phase of BMT, we retrospectively examined life-threatening or fatal cardiotoxicity identified using the complications records of our transplant center clinical database. All serious cardiac toxicity events within 100 days of BMT except those attributable to septic shock, pneumonitis or multi-organ failure were reviewed. Of 2821 BMT patients at the University of Minnesota between 1977 and 1997, 26 were identified as having suffered major or fatal (n = 13) cardiotoxicity (0.9%, 19 adults and seven children). Rapidly progressive heart failure resulted in death of 11 patients, one patient had fatal pericardial tamponade, and one had an acute ventricular fibrillation arrest. The remaining 13 patients (50%) had life-threatening cardiotoxicity including four patients with pericardial tamponade and nine patients with cardiac arrhythmias. Overall, we observed that acute, major cardiotoxic events attributable to BMT are uncommon, occurring with a frequency of <1%. These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity.
心脏并发症可能源于骨髓和血液干细胞移植(BMT)预处理阶段给予的高剂量化疗或放疗。为评估与BMT急性期相关的临床严重心脏毒性的发生率,我们回顾性研究了利用本移植中心临床数据库并发症记录确定的危及生命或致命的心脏毒性。对BMT后100天内所有严重心脏毒性事件进行了审查,但不包括由感染性休克、肺炎或多器官衰竭引起的事件。在1977年至1997年间明尼苏达大学的2821例BMT患者中,有26例被确定发生了严重或致命(n = 13)心脏毒性(0.9%,19例成人和7例儿童)。快速进展性心力衰竭导致11例患者死亡,1例患者发生致命性心包填塞,1例发生急性心室颤动骤停。其余13例患者(50%)发生危及生命的心脏毒性,包括4例心包填塞患者和9例心律失常患者。总体而言,我们观察到BMT所致的急性、严重心脏毒性事件并不常见,发生率<1%。这些数据表明,通过适当的移植前临床评估,BMT预处理阶段的高剂量环磷酰胺和放疗不会导致频繁的、具有临床相关性的短期心脏毒性。